Compare ENTX & MATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTX | MATH |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | Israel | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.0M | 145.4M |
| IPO Year | 2018 | N/A |
| Metric | ENTX | MATH |
|---|---|---|
| Price | $2.37 | $2.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 107.9K | ★ 115.0K |
| Earning Date | 11-14-2025 | 12-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.41 |
| Revenue | $124,000.00 | ★ $44,567,257.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.63 |
| Revenue Growth | 25.25 | ★ 165.86 |
| 52 Week Low | $1.50 | $0.88 |
| 52 Week High | $3.22 | $4.17 |
| Indicator | ENTX | MATH |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 41.92 |
| Support Level | $2.26 | $2.75 |
| Resistance Level | $2.53 | $3.03 |
| Average True Range (ATR) | 0.23 | 0.22 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 6.05 | 30.43 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.